

Avner Reshef

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3987562/publications.pdf>

Version: 2024-02-01

46
papers

2,837
citations

279701

23
h-index

243529

44
g-index

49
all docs

49
docs citations

49
times ranked

1281
citing authors

#	ARTICLE	IF	CITATIONS
1	Icatibant, a New Bradykinin-Receptor Antagonist, in Hereditary Angioedema. <i>New England Journal of Medicine</i> , 2010, 363, 532-541.	13.9	477
2	2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. <i>Allergy, Asthma and Clinical Immunology</i> , 2010, 6, 24.	0.9	443
3	Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. <i>Journal of Allergy and Clinical Immunology</i> , 2009, 124, 801-808.	1.5	311
4	Randomized placebo-controlled trial of the bradykinin B2 receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial. <i>Annals of Allergy, Asthma and Immunology</i> , 2011, 107, 529-537.e2.	0.5	187
5	Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 Inhibitor. <i>New England Journal of Medicine</i> , 2017, 376, 1131-1140.	13.9	169
6	The international WAO/EAACI guideline for the management of hereditary angioedemaâ€”The 2021 revision and update. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 1961-1990.	2.7	153
7	HAE international home therapy consensus document. <i>Allergy, Asthma and Clinical Immunology</i> , 2010, 6, 22.	0.9	149
8	Recombinant human C1-esterase inhibitor relieves symptoms of hereditary angioedema attacks: phase 3, randomized, placebo-controlled trial. <i>Annals of Allergy, Asthma and Immunology</i> , 2014, 112, 163-169.e1.	0.5	70
9	Long-Term Outcomes with Subcutaneous C1-Inhibitor Replacement Therapy for Prevention of Hereditary Angioedema Attacks. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 1793-1802.e2.	2.0	58
10	Recombinant human C1 esterase inhibitor for prophylaxis of hereditary angio-oedema: a phase 2, multicentre, randomised, double-blind, placebo-controlled crossover trial. <i>Lancet, The</i> , 2017, 390, 1595-1602.	6.3	55
11	The Hypereosinophilic Syndrome Associated with CD4 ⁺ CD3 ⁺ Helper Type 2 (Th2) Lymphocytes. <i>Leukemia and Lymphoma</i> , 2001, 42, 123-133.	0.6	54
12	A rapid Percoll technique for the purification of human basophils. <i>Journal of Immunological Methods</i> , 1987, 105, 107-110.	0.6	48
13	Psychometric Field Study of Hereditary Angioedema Quality of Life Questionnaire for Adults: HAE-QoL. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2016, 4, 464-473.e4.	2.0	48
14	Angiotensin-converting enzyme inhibitorâ€”induced angioedema in a community hospital emergency department. <i>Annals of Allergy, Asthma and Immunology</i> , 2009, 103, 502-507.	0.5	47
15	Signs and symptoms preceding acute attacks of hereditary angioedema: Results of three recent surveys. <i>Allergy and Asthma Proceedings</i> , 2013, 34, 261-266.	1.0	44
16	International Consensus on the Use of Genetics in the Management of Hereditary Angioedema. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 901-911.	2.0	43
17	Treatment Effect and Safety of Icatibant in Pediatric Patients with Hereditary Angioedema. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2017, 5, 1671-1678.e2.	2.0	39
18	The Story of Angioedema: from Quincke to Bradykinin. <i>Clinical Reviews in Allergy and Immunology</i> , 2016, 51, 121-139.	2.9	38

#	ARTICLE	IF	CITATIONS
19	The international WAO/EAACI guideline for the management of hereditary angioedema – The 2021 revision and update. <i>World Allergy Organization Journal</i> , 2022, 15, 100627.	1.6	37
20	C1-INH concentrate for treatment of acute hereditary angioedema: a pediatric cohort from the I.M.P.A.C.T. studies. <i>Pediatric Allergy and Immunology</i> , 2013, 24, 54-60.	1.1	32
21	Recombinant Human-C1 Inhibitor Is Effective and Safe for Repeat Hereditary Angioedema Attacks. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2015, 3, 417-423.	2.0	32
22	Population pharmacokinetics of plasma-derived C1 esterase inhibitor concentrate used to treat acute hereditary angioedema attacks. <i>Annals of Allergy, Asthma and Immunology</i> , 2010, 105, 149-154.	0.5	31
23	Definition, aims, and implementation of GA ² LEN/HAEi Angioedema Centers of Reference and Excellence. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 2115-2123.	2.7	29
24	Impact of an extended challenge on the effectiveness of I ² -lactam hypersensitivity investigation. <i>Annals of Allergy, Asthma and Immunology</i> , 2016, 116, 329-333.	0.5	28
25	Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet, The</i> , 2022, 399, 945-955.	6.3	28
26	Long-term safety and effectiveness of berotralstat for hereditary angioedema: The open-label APEX study. <i>Clinical and Translational Allergy</i> , 2021, 11, e12035.	1.4	22
27	Recombinant human C1 esterase inhibitor treatment for hereditary angioedema attacks in children. <i>Pediatric Allergy and Immunology</i> , 2019, 30, 562-568.	1.1	18
28	Mitigating Disparity in Health-care Resources Between Countries for Management of Hereditary Angioedema. <i>Clinical Reviews in Allergy and Immunology</i> , 2021, 61, 84-97.	2.9	16
29	Long-term efficacy and safety of subcutaneous C1-inhibitor in women with hereditary angioedema: subgroup analysis from an open-label extension of a phase 3 trial. <i>Allergy, Asthma and Clinical Immunology</i> , 2020, 16, 8.	0.9	16
30	Immunogold probe for the light-microscopic phenotyping of human mast cells and basophils. <i>Journal of Immunological Methods</i> , 1987, 99, 213-219.	0.6	14
31	Hereditary angioedema: new hopes for an orphan disease. <i>Israel Medical Association Journal</i> , 2008, 10, 850-5.	0.1	13
32	Hereditary angioedema: Validation of the end point time to onset of relief by correlation with symptom intensity. <i>Allergy and Asthma Proceedings</i> , 2011, 32, 36-42.	1.0	10
33	Long-Term Efficacy of Subcutaneous C1 Inhibitor in Pediatric Patients with Hereditary Angioedema. <i>Pediatric, Allergy, Immunology, and Pulmonology</i> , 2020, 33, 136-141.	0.3	10
34	Biomarkers in Hereditary Angioedema. <i>Clinical Reviews in Allergy and Immunology</i> , 2021, 60, 404-415.	2.9	10
35	Recombinant Human C1-Esterase Inhibitor to Treat Acute Hereditary Angioedema Attacks in Adolescents. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2017, 5, 1091-1097.	2.0	9
36	A Structured Gradual Exposure Protocol to Baked and Heated Milk in the Treatment of Milk Allergy. <i>Journal of Pediatrics</i> , 2018, 203, 204-209.e2.	0.9	9

#	ARTICLE	IF	CITATIONS
37	Effects of Continuous Plasma-Derived Subcutaneous C1-Esterase Inhibitor on Coagulation and Fibrinolytic Parameters. <i>Thrombosis and Haemostasis</i> , 2021, 121, 690-693.	1.8	9
38	The Enigma of Prodromes in Hereditary Angioedema (HAE). <i>Clinical Reviews in Allergy and Immunology</i> , 2021, 61, 15-28.	2.9	9
39	Efficacy of recombinant human C1 esterase inhibitor for the treatment of severe hereditary angioedema attacks. <i>Allergy and Asthma Proceedings</i> , 2017, 38, 456-461.	1.0	8
40	New Instrument for the Evaluation of Prodromes and Attacks of Hereditary Angioedema (HAE-EPA). <i>Clinical Reviews in Allergy and Immunology</i> , 2021, 61, 29-39.	2.9	5
41	The prophylaxis of hereditary angioedema attacks with recombinant human C1 inhibitor: who will take advantage of the individualized treatment approach?. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2013, 68, 1207-1209.	2.7	4
42	Case Title: 45 year-old male with recurrent angioedema: WAO international case-based discussions. <i>World Allergy Organization Journal</i> , 2014, 7, 2.	1.6	2
43	Prodromes as predictors of hereditary angioedema attacks. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 1309-1312.	2.7	2
44	Sustained Response Following Acute Treatment Of Hereditary Angioedema Attacks With Recombinant Human C1 Esterase Inhibitor. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, AB37.	1.5	1
45	Hereditary angioedema: A call for collective terminology. <i>Allergy and Asthma Proceedings</i> , 2016, 37, 14-14.	1.0	0
46	Continued icatibant use across recurrent attacks in adolescents with hereditary angioedema. <i>Pediatric Allergy and Immunology</i> , 2021, 32, 1392-1396.	1.1	0